Oppenheimer analyst Suraj Kalia downgraded Edwards Lifesciences (EW) to Perform from Outperform.
Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
Published first on TheFly – the ultimate source for real-time, market-moving breaking financial news. Try Now>>
Read More on EW:
- Netflix upgraded, Dollar Tree downgraded: Wall Street’s top analyst calls
- Edwards Lifesciences upgraded to Outperform from In Line at Evercore ISI
- Edwards Lifesciences price target lowered to $85 from $95 at Stifel
- Edwards Lifesciences management to meet with Piper Sandler
- Edwards Lifesciences: Strategic Positioning and Growth Potential Drive Buy Rating Amid TAVR Market Expansion